Publikationen, an denen er mitarbeitet Francisco de Borja Hernández Breijo (13)

2022

  1. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

2020

  1. Dendritic nanotheranostic for the delivery of infliximab: A potential carrier in rheumatoid arthritis therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-17

  2. Extracellular allograft inflammatory factor-1 (AIF-1) potentiates Th1 cell differentiation and inhibits Treg response in human peripheral blood mononuclear cells from normal subjects

    Human Immunology, Vol. 81, Núm. 2-3, pp. 91-100

  3. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

2017

  1. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease

    Biomarkers, Vol. 22, Núm. 2, pp. 133-144

2016

  1. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41

2014

  1. Effect of Infliximab in oxidised serum albumin levels during experimental colitis

    Biomarkers, Vol. 19, Núm. 8, pp. 693-701

2013

  1. Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1

    Toxicology and Applied Pharmacology, Vol. 272, Núm. 3, pp. 568-578

2012

  1. Is the autophagy induced by thiopurines beneficial or deleterious?

    Current Drug Metabolism, Vol. 13, Núm. 9, pp. 1267-1276

2011

  1. La Azatioprina induce autofagia en células HepG2

    Terceras Jornadas de Jóvenes Investigadores de la Universidad de Alcalá

  2. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma

    World Journal of Gastroenterology, Vol. 17, Núm. 34, pp. 3899-3911

2009

  1. RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-α-induced cell death in hepatocarcinoma cancer cell lines

    Journal of Cellular Biochemistry, Vol. 108, Núm. 6, pp. 1292-1301